# TibaTrace Penetration Testing Report — Assessment Status

**Status:** No independent penetration test result found in the reviewed repository  
**Report date:** 17 October 2026  
**Test window/provider:** Not conducted / not supplied  
**Disposition:** This document is a transparent status report and test charter. It is not evidence that TibaTrace passed a penetration test.

## 1. Executive statement

The repository and available release evidence do not contain an independent, authorized penetration test report for the current production system. No black-box or authenticated testing of the live service is claimed in this document. It would be misleading to report “zero vulnerabilities,” assign a pass rating, or mark penetration testing complete.

## 2. Proposed test scope

Before testing, agree the target release, written authorization, source IPs, test accounts/roles, tenant fixtures, dates, rate limits, data-handling terms, escalation channel, excluded actions and stop conditions.

Recommended scope:

- Public web/HQ and API perimeter, TLS, session/CSRF, authentication and password reset.
- Tenant boundary and object-level authorization across HQ, APIs, FHIR, documents, reports and POS activation.
- Role/capability escalation, platform-owner functions, tenant/branch scoping and service accounts.
- Patient identifier reveal, clinical records, attachments, exports and audit events.
- Prescription, clinical gate, payment/recovery, refund, stock reservation, reconciliation and recall workflows.
- Provider callback, idempotency, credential storage, signing and integration activation paths (only if a test adapter is authorized/configured).
- Dependency/container/image configuration, secrets handling, deployment rollback and backup/restore access boundaries.
- Windows/Android client storage, update/signing, offline behavior and local device data where included in the signed scope.

Use synthetic records only. Do not perform destructive production actions, real payments, drug dispensing, unapproved load tests, or third-party testing without the affected provider's authorization.

## 3. Required deliverables from tester

The signed report must identify tester and independence, authorization, dates, target source/image digests, test methodology, coverage and exclusions, accounts/roles, evidence handling, finding severity and exploitability, reproducible proof with sensitive data redacted, business impact, remediation, retest result and residual risk. Critical/high findings require a retest before certification or release approval.

## 4. Existing security evidence is not a penetration test

The rc52 release record reports CI test coverage, tenant/owner access checks, dependency and runtime image scans without findings, release checksums and image provenance. These are valuable release gates but do not replace manual exploitation attempts or an independent penetration test. The subsequent rc53 candidate work has no production verification record in the reviewed document set.

## 5. Approval and next action

**Status:** Open  
**Owner:** Esenai security/service owner (to assign)  
**Target date/provider:** `[to schedule]`  
**Test authorization:** `[signed scope required]`  
**Final disposition:** Pending independent test and remediation retest
